Project Grant R01DA064588
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $796K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $100,228 on October 8, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on opioid reward mechanisms. The award funds a project investigating the functional role of a novel cortical circuit connecting the dorsal peduncular nucleus to the ventral tegmental area in mediating opioid reward. The research employs barcoded anatomy resolved by sequencing combined with spatial...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.352 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct single-molecule functional validation of neurogenomic alterations in opioid-exposed HIV brain tissue. The project performs single-molecule fiber-seq profiling on cingulate cortex tissue samples from the SCORCH (Single Cell Opioid Response in the Context of HIV) consortium, analyzing approximately...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $2.35 million on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to mine transcriptomic datasets and resolve functionally relevant striatal cell types in response to HIV infection and opioid use. The recipient will analyze single-nucleus RNA sequencing, two-dimensional single-cell spatial transcriptomic, and three-dimensional single-cell spatial transcriptomic data generated...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $720,691 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to design and develop blood-brain barrier-crossing conjugates that enable delivery of antisense oligonucleotides to the brain for treating cocaine use disorder. The project addresses the lack of FDA-approved medications for cocaine use disorder by leveraging recent advances in antisense oligonucleotide technologies to...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai a cooperative agreement valued at $749,153 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a phased, randomized, double-blind clinical trial testing transcranial direct current stimulation (tDCS) over the right dorsolateral prefrontal cortex to reduce craving and cue reactivity in patients with opioid use disorder. The study will randomize 60 inpatients with...
- The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $181,092 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate dopamine receptor type 2 (D2)-expressing cells in the ventral hippocampus and their role in cocaine relapse vulnerability. The research comprises three aims conducted in New York, NY through April 30, 2028. Aim 1 characterizes ventral hippocampus D2 neuron activity during cocaine intravenous...
- The National Institute on Drug Abuse awarded the Lieber Institute Inc. $1.855 million on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop three-dimensional cellular resolution spatio-molecular maps of the human nucleus accumbens across its anterior-posterior axis. The nucleus accumbens is a key node in the brain's reward circuitry, and perturbations in reward signaling are implicated in substance use disorders. The project extends prior spatial...
- The National Institute on Drug Abuse awarded New York University $103,607 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct dissertation research on polysubstance use patterns and their associations with methadone maintenance treatment receipt and discontinuation among people who use drugs in New York State. The research uses a mixed-methods approach guided by the Social Ecological Model to identify latent polysubstance use patterns through urine...
- The National Institute on Drug Abuse awarded Drexel University $832,132 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate novel circuit mechanisms underlying opioid-induced dopamine elevations in the nucleus accumbens, operating beyond the canonical midbrain dopamine neuron pathway. The research explores how oxycodone enhances dopamine signals through local circuits in the nucleus accumbens, specifically examining the role of GABA and cholinergic...
- The National Institute on Drug Abuse awarded The Washington University $1,155,062 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to generate multiomics data characterizing cellular mechanisms underlying fentanyl-induced respiratory depression in opioid overdose decedents. The award funds single-nucleus RNA-seq and ATAC-seq (snRNAseq and snATACseq) paired multiomics analysis of brainstem respiratory control regions—the prebotzinger complex and ventral...